Hôpital de Cayenne, Service d’Endocrinologie et des Maladies Métaboliques, Cayenne, Guyane Française
Search for other papers by Nadia Sabbah in
Google Scholar
PubMed
Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
Search for other papers by Peter Wolf in
Google Scholar
PubMed
Search for other papers by Céline Piedvache in
Google Scholar
PubMed
Search for other papers by Séverine Trabado in
Google Scholar
PubMed
Search for other papers by Tristan Verdelet in
Google Scholar
PubMed
Search for other papers by Catherine Cornu in
Google Scholar
PubMed
Search for other papers by Jean-Claude Souberbielle in
Google Scholar
PubMed
Search for other papers by Philippe Chanson in
Google Scholar
PubMed
Introduction IGF-1 measurement is important for the diagnosis and management of patients with growth hormone (GH) deficiency or acromegaly as well as in their follow-up ( 1 , 2 ). We previously established normative data for six IGF-I assays
Search for other papers by Gudmundur Johannsson in
Google Scholar
PubMed
Search for other papers by Martin Bidlingmaier in
Google Scholar
PubMed
Search for other papers by Beverly M K Biller in
Google Scholar
PubMed
Search for other papers by Margaret Boguszewski in
Google Scholar
PubMed
Search for other papers by Felipe F Casanueva in
Google Scholar
PubMed
Search for other papers by Philippe Chanson in
Google Scholar
PubMed
Search for other papers by Peter E Clayton in
Google Scholar
PubMed
Search for other papers by Catherine S Choong in
Google Scholar
PubMed
Search for other papers by David Clemmons in
Google Scholar
PubMed
Search for other papers by Mehul Dattani in
Google Scholar
PubMed
Search for other papers by Jan Frystyk in
Google Scholar
PubMed
Search for other papers by Ken Ho in
Google Scholar
PubMed
Search for other papers by Andrew R Hoffman in
Google Scholar
PubMed
Search for other papers by Reiko Horikawa in
Google Scholar
PubMed
Search for other papers by Anders Juul in
Google Scholar
PubMed
Search for other papers by John J Kopchick in
Google Scholar
PubMed
Search for other papers by Xiaoping Luo in
Google Scholar
PubMed
Search for other papers by Sebastian Neggers in
Google Scholar
PubMed
Search for other papers by Irene Netchine in
Google Scholar
PubMed
Search for other papers by Daniel S Olsson in
Google Scholar
PubMed
Search for other papers by Sally Radovick in
Google Scholar
PubMed
Search for other papers by Ron Rosenfeld in
Google Scholar
PubMed
Search for other papers by Richard J Ross in
Google Scholar
PubMed
Search for other papers by Katharina Schilbach in
Google Scholar
PubMed
Search for other papers by Paulo Solberg in
Google Scholar
PubMed
Search for other papers by Christian Strasburger in
Google Scholar
PubMed
Search for other papers by Peter Trainer in
Google Scholar
PubMed
Search for other papers by Kevin C J Yuen in
Google Scholar
PubMed
Search for other papers by Kerstin Wickstrom in
Google Scholar
PubMed
Search for other papers by Jens O L Jorgensen in
Google Scholar
PubMed
Search for other papers by on behalf of the Growth Hormone Research Society in
Google Scholar
PubMed
factor-I (IGF-I). Both are used diagnostically; IGF-I is used to monitor the effects of GH replacement in GH deficiency (GHD), and both GH and IGF-I are used in the diagnosis and management of acromegaly. While serum IGF-I level is used as a surrogate
Search for other papers by P R van Dijk in
Google Scholar
PubMed
Diabetes Centre, Departments of Internal Medicine, General Practice, Langerhans Medical Research Group, Department of Internal Medicine, Division of Cell Biology, Faculty of Health Sciences, Isala Clinics, PO Box 10400, 8000 G.K. Zwolle, The Netherlands
Search for other papers by S J J Logtenberg in
Google Scholar
PubMed
Diabetes Centre, Departments of Internal Medicine, General Practice, Langerhans Medical Research Group, Department of Internal Medicine, Division of Cell Biology, Faculty of Health Sciences, Isala Clinics, PO Box 10400, 8000 G.K. Zwolle, The Netherlands
Search for other papers by K H Groenier in
Google Scholar
PubMed
Diabetes Centre, Departments of Internal Medicine, General Practice, Langerhans Medical Research Group, Department of Internal Medicine, Division of Cell Biology, Faculty of Health Sciences, Isala Clinics, PO Box 10400, 8000 G.K. Zwolle, The Netherlands
Diabetes Centre, Departments of Internal Medicine, General Practice, Langerhans Medical Research Group, Department of Internal Medicine, Division of Cell Biology, Faculty of Health Sciences, Isala Clinics, PO Box 10400, 8000 G.K. Zwolle, The Netherlands
Search for other papers by N Kleefstra in
Google Scholar
PubMed
Diabetes Centre, Departments of Internal Medicine, General Practice, Langerhans Medical Research Group, Department of Internal Medicine, Division of Cell Biology, Faculty of Health Sciences, Isala Clinics, PO Box 10400, 8000 G.K. Zwolle, The Netherlands
Diabetes Centre, Departments of Internal Medicine, General Practice, Langerhans Medical Research Group, Department of Internal Medicine, Division of Cell Biology, Faculty of Health Sciences, Isala Clinics, PO Box 10400, 8000 G.K. Zwolle, The Netherlands
Search for other papers by H J G Bilo in
Google Scholar
PubMed
Diabetes Centre, Departments of Internal Medicine, General Practice, Langerhans Medical Research Group, Department of Internal Medicine, Division of Cell Biology, Faculty of Health Sciences, Isala Clinics, PO Box 10400, 8000 G.K. Zwolle, The Netherlands
Search for other papers by H J Arnqvist in
Google Scholar
PubMed
the start of the s.c. and i.p. insulin treatment phases were respectively 83.7±31.9 and 76.3±24.5 μg/l. IGF1 and IGFBP1 concentrations Results obtained for the IGF1 and IGFBP1 measurements during the different treatment modalities are summarized in
Search for other papers by Urszula Smyczyńska in
Google Scholar
PubMed
Search for other papers by Joanna Smyczyńska in
Google Scholar
PubMed
Department of Paediatric Endocrinology, Medical University of Lodz, Lodz, Poland
Search for other papers by Maciej Hilczer in
Google Scholar
PubMed
Search for other papers by Renata Stawerska in
Google Scholar
PubMed
Search for other papers by Ryszard Tadeusiewicz in
Google Scholar
PubMed
Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, Lodz, Poland
Search for other papers by Andrzej Lewiński in
Google Scholar
PubMed
), in some of them also concentrations of IGF-I ( 7 , 8 , 9 , 13 ) and IGFBP-3 ( 7 , 9 ) have been processed. The most frequently used method of deriving models of GH therapy outcomes has been multiple linear regression (MLR) ( 6 , 7 , 10 , 11
Search for other papers by M Krause in
Google Scholar
PubMed
Search for other papers by H Frederiksen in
Google Scholar
PubMed
Search for other papers by K Sundberg in
Google Scholar
PubMed
Search for other papers by F S Jørgensen in
Google Scholar
PubMed
Search for other papers by L N Jensen in
Google Scholar
PubMed
Search for other papers by P Nørgaard in
Google Scholar
PubMed
Search for other papers by C Jørgensen in
Google Scholar
PubMed
Search for other papers by P Ertberg in
Google Scholar
PubMed
Section of Biostatistics, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark
Search for other papers by J H Petersen in
Google Scholar
PubMed
Search for other papers by U Feldt-Rasmussen in
Google Scholar
PubMed
Search for other papers by A Juul in
Google Scholar
PubMed
Search for other papers by K T Drzewiecki in
Google Scholar
PubMed
Search for other papers by N E Skakkebaek in
Google Scholar
PubMed
Search for other papers by A M Andersson in
Google Scholar
PubMed
factor I (IGF-I) and its major binding protein: insulin-like growth factor-binding protein-3 (IGFBP3). IGF-I and IGFBP3 were both measured by a chemiluminescence immunoassay on the IDS-iSYS automated platform (Immuno Diagnostic Systems, IDS) at the
Department of Nutritional Sciences, University of Toronto, Toronto, Canada
Search for other papers by Monika Bilic in
Google Scholar
PubMed
Department of Nutritional Sciences, University of Toronto, Toronto, Canada
Search for other papers by Huma Qamar in
Google Scholar
PubMed
Search for other papers by Akpevwe Onoyovwi in
Google Scholar
PubMed
Search for other papers by Jill Korsiak in
Google Scholar
PubMed
Search for other papers by Eszter Papp in
Google Scholar
PubMed
Search for other papers by Abdullah Al Mahmud in
Google Scholar
PubMed
Molecular and Medical Genetics, University of Toronto, Toronto, Canada
Department of Paediatrics, Hospital for Sick Children and University of Toronto, Toronto, Canada
Search for other papers by Rosanna Weksberg in
Google Scholar
PubMed
Search for other papers by Alison D Gernand in
Google Scholar
PubMed
Search for other papers by Jennifer Harrington in
Google Scholar
PubMed
Department of Nutritional Sciences, University of Toronto, Toronto, Canada
Department of Paediatrics, Hospital for Sick Children and University of Toronto, Toronto, Canada
Search for other papers by Daniel E Roth in
Google Scholar
PubMed
improve growth-related outcomes. The insulin-like growth factor (IGF) axis includes several signal and binding proteins, many of which are under the regulation of growth hormone. IGF-I is the primary regulator of fetal growth, and its circulating
Search for other papers by Werner F Blum in
Google Scholar
PubMed
Search for other papers by Abdullah Alherbish in
Google Scholar
PubMed
Search for other papers by Afaf Alsagheir in
Google Scholar
PubMed
Search for other papers by Ahmed El Awwa in
Google Scholar
PubMed
Search for other papers by Walid Kaplan in
Google Scholar
PubMed
Search for other papers by Ekaterina Koledova in
Google Scholar
PubMed
Search for other papers by Martin O Savage in
Google Scholar
PubMed
Introduction The growth hormone (GH)–insulin-like growth factor (IGF)-I axis is the principle endocrine system regulating linear growth in children ( 1 ). Linked to the nutritional status of the individual, GH is a potent stimulator of IGF-I
Search for other papers by Mieke Van Hemelrijck in
Google Scholar
PubMed
Search for other papers by Thurkaa Shanmugalingam in
Google Scholar
PubMed
Search for other papers by Cecilia Bosco in
Google Scholar
PubMed
Search for other papers by Wahyu Wulaningsih in
Google Scholar
PubMed
Search for other papers by Sabine Rohrmann in
Google Scholar
PubMed
's College London. References 1 Furstenberger G Senn HJ . Insulin-like growth factors and cancer . Lancet Oncology 2002 3 298 – 302 . ( doi:10.1016/S1470-2045(02)00731-3 ). 2 Colao A . The GH–IGF-I axis and the cardiovascular system: clinical
Search for other papers by Martin Bidlingmaier in
Google Scholar
PubMed
Search for other papers by Helena Gleeson in
Google Scholar
PubMed
Search for other papers by Ana-Claudia Latronico in
Google Scholar
PubMed
Search for other papers by Martin O Savage in
Google Scholar
PubMed
of benefit) based on scientific evidence ( 5 ). IGF-I as a biomarker for GH status Many components in the blood are sensitive to GH and so could be candidate biomarkers for GH levels and, thus, be used to determine GH deficiency and the need for
Search for other papers by Elvira C Arellanes-Licea in
Google Scholar
PubMed
Search for other papers by José Ávila-Mendoza in
Google Scholar
PubMed
Search for other papers by Elizabeth C Ramírez-Martínez in
Google Scholar
PubMed
Search for other papers by Eugenia Ramos in
Google Scholar
PubMed
Search for other papers by Nancy Uribe-González in
Google Scholar
PubMed
Search for other papers by Carlos Arámburo in
Google Scholar
PubMed
Search for other papers by Teresa Morales in
Google Scholar
PubMed
Search for other papers by Maricela Luna in
Google Scholar
PubMed
://doi.org/10.1159/000262529 ) 21 Isgaard J Aberg D Nilsson M. Protective and regenerative effects of the GH/IGF-I axis on the brain . Minerva Endocrinologica 2007 32 103 – 113 . 22 Arce VM Devesa P Devesa J. Role of growth hormone (GH) in the